pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,053 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT967Endpoints742BioPharma Dive283BioSpace181Fierce Biotech172onclive165globenewswire health73raps
therapy area
allOncology5621Rare Disease1252Cardiology1054Hematology940Immunology932Vaccines816Pulmonology
  • WuXi AppTec added to Pentagon's list of companies linked to Chinese military
    Another wave of scrutiny has hit WuXi AppTec through its re-inclusion in the Pentagon’s updated list of companies that have ties to the Chinese military. With its appearance on the list ...
    Endpoints · 2mo ago↗ source
  • Opinion: Ending animal testing could set back xenotransplantation just as the field is poised for a breakthrough
    “Innovations like xenotransplantation would never have reached clinical trials without animal experimentation,” writes transplant surgeon Joshua Mezrich.
    STAT · 2mo ago↗ source
  • STAT+: Wearables, and the flood of data they generate, inch closer to entering the clinic
    Wearables generate a lot of health data, but it exists outside the clinic for the most part. New moves from Oura and Whoop may change that.
← prev
page 48 of 83
next →
65
fda recalls41
fda medwatch32
fda press25
782
Psychiatry & CNS691
Ophthalmology347
Pain342
Endocrinology & Metabolism340
Infectious Disease331
STAT · 2mo ago
↗ source
  • Opinion: Why STAT is sticking with ‘health care’ as two words
    Is it “health care” or “healthcare”? STAT readers had strong feelings.
    STAT · 2mo ago↗ source
  • STAT+: Trump’s health care affordability czar touts Medicaid cuts to hospital leaders
    Hospital execs say they're working to mitigate the impacts of the looming cuts.
    STAT · 2mo ago↗ source
  • A leader of the 2014 U.S. Ebola response compares then to now
    As the world deals with an outbreak of Ebola that has no known cure, Susan Reichle, who last year co-founded Aid Transition Alliance to support former USAID professionals, discusses the…
    STAT · 2mo ago↗ source
  • STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
    GSK is buying Nuvalent, the maker of targeted cancer drugs, for $10.6 billion, a sizable addition to the latest run of biopharma acquisitions.
    STAT · 2mo ago↗ source
  • GSK to acquire Nuvalent and its two cancer drugs under FDA review for $10.6B
    GSK is making one of the largest biotech acquisitions in its history to gain access to two experimental lung cancer medicines that are due for FDA approval decisions later this year. The UK drugmak…
    Endpoints · 2mo ago↗ source
  • Alcohol study discarded by Trump officials is published in scientific journal
    A government-commissioned study had been meant to inform new dietary guidelines, and found risks associated with even light drinking.
    STAT · 2mo ago↗ source
  • Health workers at the epicenter of Congo’s Ebola outbreak labor with little pay or rest
    Health workers at the epicenter of Congo's Ebola outbreak are laboring with little pay or rest.
    STAT · 2mo ago↗ source
  • #ADA26: AstraZeneca's GLP-1 pill cuts weight by 10.5% after six months
    The race to be third to market with an obesity pill has a number of contenders, including Roche, Pfizer and Structure Therapeutics. On Monday, AstraZeneca set out its own stall with data on a pill ...
    Endpoints · 2mo ago↗ source
  • STAT+: AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trials
    AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how it stacks up against other oral treatments.
    STAT · 2mo ago↗ source
  • Incyte CEO sees $2B Vega deal aiding a post-Jakafi future
    Bill Meury has been in or led the C-suite of several biopharma companies that have constructed multibillion-dollar exits over the past decade: Allergan, Karuna and Anthos. Now, he’s the one buying.…
    Endpoints · 2mo ago↗ source
  • City Therapeutics gets $99M to gather data on three RNAi medicines
    City Therapeutics, the next-gen RNAi startup founded and led by former Alnylam executives, has collected $99.5 million to fund the clinical development of its first three candidates and expand into…
    Endpoints · 2mo ago↗ source
  • GoHealth files for bankruptcy, as Medicare Advantage insurers pull back
    The volatile Medicare Advantage market can now count GoHealth as a casualty. GoHealth, a health insurance marketplace focused on seniors, on Sunday voluntarily filed for Chapter 11 bankruptcy in th…
    Endpoints · 2mo ago↗ source
  • Treeline to go public via reverse merger with Standard BioTools
    Treeline Biosciences has shared plans to debut on public markets through a reverse merger with Standard BioTools in a move that should give the company a cash runway through 2029. The
    Endpoints · 2mo ago↗ source
  • STAT+: UnitedHealthcare’s lactation billing feud, and fake strokes
    The biggest U.S. health insurer is changing how it pays for lactation counseling, and it could cut payment for many providers.
    STAT · 2mo ago↗ source
  • J&J makes $1B move for Firefly Bio, Carolyn Bertozzi's twist on ADCs in KRAS field
    Johnson & Johnson is making another early-stage oncology deal, dishing out $1 billion in cash to acquire Firefly Bio, a preclinical startup working on degrader antibody conjugates. J&J now joins th…
    Endpoints · 2mo ago↗ source
  • GSK inks multi-target pact with Engitix; Sangamo considers strategic options
    Plus news about Pfizer's latest label expansion. 🤝 GSK inks multi-target liver pact with Engitix: London-based Engitix will use disease models based on its extracellular matrix technology to ident…
    Endpoints · 2mo ago↗ source
  • Tango plans Phase 3 pancreatic cancer study after combo success
    Will 2026 be remembered as the year when pancreatic cancer finally became treatable? Following Revolution Medicines’ smashing success at the annual American Society of Clinical Oncology meeting las…
    Endpoints · 2mo ago↗ source
  • Coming Soon
    Next installments of the biopharma pay series coming soon
    Endpoints · 2mo ago↗ source
  • STAT+: Novo underwhelmed by drug it once fought Pfizer for
    Revolution and Tango yield promising cancer results, Incyte buys bleeding disorder drug, and more biotech news
    STAT · 2mo ago↗ source
  • Biopharma's top-paid CEOs of 2025: 25 making $25M+
    For the first time in four years, Endpoints News is raising the bar for what it means to be a top-paid CEO. The previous floor of $20 million is no longer rich enough. The biopharma ...
    Endpoints · 2mo ago↗ source
  • Cavalry Biosciences pursues $75M Series B to test eye and muscle disorder drugs
    Cavalry Biosciences, the first biotech out of incubator and investor Jupiter Bioventures, is working on a $75 million Series B to bring its first two drug candidates into clinical testing, CEO Pres…
    Endpoints · 2mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about Lilly and Pfizer obesity drug data, Roche and J&J deals, and more
    Lilly disclosed new data that provide more details on the safety and tolerability of its next-generation obesity drug retatrutide
    STAT · 2mo ago↗ source